52.42
price up icon4.05%   2.04
 
loading
Celcuity Inc stock is traded at $52.42, with a volume of 956.25K. It is up +4.05% in the last 24 hours and up +276.04% over the past month. Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$50.38
Open:
$51
24h Volume:
956.25K
Relative Volume:
0.96
Market Cap:
$2.04B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-19.56
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+1.22%
1M Performance:
+276.04%
6M Performance:
+298.63%
1Y Performance:
+210.55%
1-Day Range:
Value
$50.31
$52.67
1-Week Range:
Value
$47.34
$53.05
52-Week Range:
Value
$7.575
$53.85

Celcuity Inc Stock (CELC) Company Profile

Name
Name
Celcuity Inc
Name
Phone
763-392-0767
Name
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Name
Employee
87
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CELC's Discussions on Twitter

Compare CELC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CELC
Celcuity Inc
52.42 2.19B 0 -63.78M -53.91M -2.68
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-01-25 Resumed Stifel Buy
Jul-22-24 Initiated Leerink Partners Outperform
Feb-22-24 Initiated Stifel Buy
Dec-08-23 Initiated H.C. Wainwright Buy
Oct-08-21 Initiated Canaccord Genuity Buy
Sep-07-21 Initiated Jefferies Buy
Jul-29-21 Initiated Cowen Outperform
Jul-27-21 Initiated Needham Buy
Jan-28-21 Reiterated H.C. Wainwright Buy
Dec-24-20 Reiterated H.C. Wainwright Buy
May-11-20 Resumed Craig Hallum Buy
Nov-20-18 Initiated H.C. Wainwright Buy
View All

Celcuity Inc Stock (CELC) Latest News

pulisher
Aug 20, 2025

Drawdown in Celcuity Inc. May Be Nearing EndJuly 2025 Movers & Weekly Top Performers Watchlists - thegnnews.com

Aug 20, 2025
pulisher
Aug 20, 2025

Candlestick Signal Suggests Reversal in Celcuity Inc.2025 Risk Factors & Safe Entry Trade Reports - beatles.ru

Aug 20, 2025
pulisher
Aug 20, 2025

Celcuity announces $225M combined offerings; shares down - MSN

Aug 20, 2025
pulisher
Aug 19, 2025

Celcuity price target raised to $66 from $50 at H.C. Wainwright - MSN

Aug 19, 2025
pulisher
Aug 18, 2025

Celcuity stock price target raised to $66 from $50 at H.C. Wainwright - Investing.com Nigeria

Aug 18, 2025
pulisher
Aug 18, 2025

Celcuity Q2 2025 Earnings Release: Mixed Signals Amid Persistent Losses - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Celcuity Posts Another Loss in Q2 2025: Earnings Miss Expectations and Weigh on Market Sentiment - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Celcuity's Gedatolisib: A Blockbuster Opportunity in Breast Cancer Therapy - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Why Celcuity (CELC) is Poised for a High-Probability Breakout in 2025 - AInvest

Aug 17, 2025
pulisher
Aug 16, 2025

AI Trend Models Suggest Bounce for Celcuity Inc.2025 Support & Resistance & Low Risk High Win Rate Stock Picks - beatles.ru

Aug 16, 2025
pulisher
Aug 16, 2025

Celcuity Inc. (NASDAQ:CELC) Q2 2025 Earnings Call Transcript - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Celcuity: Needham Maintains Buy, PT Down to $70 from $74 - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity targets $5B addressable market as gedatolisib posts unprecedented PFS gains and patent extends to 2042 - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Stock Hits All-Time High on Gedatolisib Trial Success - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Stifel raises Celcuity stock price target to $68 on gedatolisib potential - Investing.com India

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Stock Hits All-Time High On Gedatolisib Progress - RTTNews

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity's Q2 2025 Earnings Call: Unpacking Contradictions in Data Timelines, Patient Population Insights, and Regulatory Readiness - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Q2 Results Highlight Cash Surge - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

Needham lowers Celcuity stock price target to $70 on dilution concerns - Investing.com

Aug 15, 2025
pulisher
Aug 15, 2025

Is Celcuity Inc. meeting your algorithmic filter criteriaAnalyst Upgrade & Weekly Hot Stock Watchlists - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Jefferies raises Celcuity stock price target to $79 on positive trial data - Investing.com Australia

Aug 15, 2025
pulisher
Aug 15, 2025

Predicting Celcuity Inc. trend using moving averagesJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Inc Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Reports Q2 Earnings with $455M Cash Reserve and Plans FDA NDA Filing for Gedatolisib in 2025 - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Celcuity Inc. Reports Promising Q2 2025 Results - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Smart tools for monitoring Celcuity Inc.’s price action2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Celcuity (CELC) Q2 2025 Earnings Call Transcript - AOL.com

Aug 14, 2025
pulisher
Aug 14, 2025

Earnings call transcript: Celcuity Q2 2025 earnings miss forecasts, stock reacts - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Reports 81% Increase in Operating Expenses, Q2 2025 Earnings Miss Analyst Estimates - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Transcript : Celcuity Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Expenses Jump 81 Percent - The Globe and Mail

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Inc. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Q2 Adjusted Loss Widens: A Clinical-Stage Biotechnology Company's Financial Performance - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity shares fall as second quarter loss exceeds estimates By Investing.com - Investing.com South Africa

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Q2 Adjusted Loss Widens - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity's Q1 2025 Earnings Miss: Weighing the Cost of Innovation in Biotech's High-Stakes Game - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Breakthrough Cancer Drug Results: Celcuity's Treatment Delivers Unprecedented Breast Cancer Survival Benefit - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

RSI Suggests Rebound May Be Near in Celcuity Inc.July 2025 Recap & Daily Chart Pattern Signals - thegnnews.com

Aug 14, 2025
pulisher
Aug 13, 2025

Celcuity : Corporate Presentation (Celcuity Investor Presentation V.6.16 Final) - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Diamedica Therapeutics shares rise 14.94% intraday after Celcuity's positive Phase 3 trial results. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Is a relief rally coming for Celcuity Inc. holdersJuly 2025 Update & Daily Entry Point Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Celcuity (CELC) Projected to Post Earnings on Thursday - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

Celcuity CELC 2025Q2 Earnings Preview Upside Potential on Positive Clinical Trial Results - AInvest

Aug 11, 2025
pulisher
Aug 10, 2025

Celcuity (CELC) Is Up 15.0% After Positive Phase 3 Results and $260 Million Capital Raise – Has The Bull Case Changed? - simplywall.st

Aug 10, 2025
pulisher
Aug 08, 2025

Celcuity stock hits all-time high at 46.52 USD By Investing.com - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 08, 2025

Celcuity stock hits all-time high at 46.52 USD - Investing.com India

Aug 08, 2025
pulisher
Aug 08, 2025

Celcuity Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView

Aug 08, 2025

Celcuity Inc Stock (CELC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Celcuity Inc Stock (CELC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Dalvey David
Director
Jul 28 '25
Sale
45.12
9,325
420,767
0
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):